Geron Corporation's stock experienced a significant decline of 5.15% during intraday trading on Wednesday. The movement followed the company's release of its first-quarter financial results for 2026.

The biopharmaceutical firm reported a narrowed net loss of $0.01 per diluted share for Q1 2026, an improvement from a loss of $0.03 per share in the same period last year. Revenue for the quarter reached $51.8 million, surpassing analyst expectations of $50.6 million and representing growth from $39.4 million a year earlier.

Despite reporting better-than-expected earnings and revenue figures, Geron's shares faced selling pressure in the market session. This reaction illustrates the complex dynamics of market sentiment, where stocks can decline even after positive earnings announcements due to factors such as profit-taking, valuation concerns, or forward-looking expectations among investors.